Tag Archives | momentum stocks

Biotechs Bounce Back, Dow and S&P Hit New Highs

where to buy Neurontin Biotechs Bounce Back: Up From September Lows-Markets Surge Ahead XBI Up 1.66% to $97.16 up from 3 month tech support of $95;IBB up 1.39%. Broad  rally brings Dow up 1%, S&P up 0.81% to fresh highs-strong 4 mo. trend line. Sector Winners: Tech (XLK) up 1.18%, Materials (XLB) up 1.08%, Healthcare (XLV) new high up […]

Continue Reading 0

Biotech Weakens Further: September Down 5% -Updates ABBV GWPH TSRO

see url Update 9/19 : Lightened up on Abbvie (ABBV) in low 90s with news of CA lawsuit on Humira kickbacks. Amgen (AMGN) hits 52 week high in $204 range, strong hold up 14.9% YTD. GW Pharmaceuticals (GWPH) rallies 6.61% to $159 for second day on cannabis trading frenzy; up 18.7% YTD with market cap $4.5B vs […]

Continue Reading 0

Biotech Weakness but why Large Caps?…Updates

http://oceanadesigns.net/wp-json/oembed/1.0/embed?url=http://oceanadesigns.net/envira/outdoor-kitchens/ Update: 10:10a Tesaro (TSRO) Soars 15% to $38, short covering or bargain hunters? News item: expansion of Zejula Combo Trial in NSCLC ========= Biotech Weakness in Large Caps Mid-Caps Have Continued Strength The overall market recovered from an early sell-off but there was pronounced biotech weakness as well as in healthcare stocks one of the […]

Continue Reading 0

Biotech Snapshot During a Rally Day: No Summer Doldrums…Updates

Update-2… 8/12 Biotech and Healthcare Holds on Emerging Market Down Day IBB down 0.55%,  XBI down 0.43%, XLV down 0.43% EEM down 2.13%, QQQ down 0.76%. ==== Update-1 Rally Fades a Bit into the Close Biotech stocks were mixed trading closer to the flatline after the close on light summer volume. Macro issues such as drug […]

Continue Reading 0

Rayno Biopharma Portfolio 2018 YTD: Performance Summary

9/10 Update: Long Tesaro (TSRO) We added small positions at $32 on August 21 and more on 9/7 at $35+. =============== Rayno Biopharma Performance 2018: YTD 8/4 Large Caps Begin to Outperform FBT Is the Best All Around Life Science Play up 19% YTD We have provided herein a summary of biopharma portfolio positions for […]

Continue Reading 0

Biotechs Cruise onto Green Screen: July Looks Good…Updates

Updates: 7/19 pm… Abbvie (ABBV) takes a 4.7% hit on Citron short seller call. Basis for call would be pressure from FDA and Scott Gottlieb concerning stalling by drug companies on biosimilars. Many reports cite biosimilar risk to blockbuster Humira. Merck succumbs to Trump pricing pressure with a minor Hep-C drug. Mid-caps mainly green, large caps […]

Continue Reading 0

Biotech Bull Market: ETFs and Life Science Mutual Funds 2018 YTD

Biotech Bull Market: Up 25.39% Over 2 Years With High Volatility  XBI Outperforms Up 12% YTD; FBT is Comparable, IBB lags. Three Funds did well in H1 2018 (7-9%). Biotech stocks peaked in July 2015 and reached a bottom on 10/31/16 gradually clawing their way back to a level about midway between the highs and lows […]

Continue Reading 0

Rayno BioBeat #4 2018: ASCO Biotech Momentum Continues with M&A Theme…Updates 6/29

Momentous  Biotech for June Update 6/28…A nice broad rally on Friday included the large cap biotechs with the IBB up 1.73% to $109.82. Even Celgene (CELG) found buyers up 3.6% flirting with the $80 level. The big winner was Vertex (VRTX) up 15.16% to the $170 level on news that a rival Company Galapagos (GLPG) […]

Continue Reading 0

Mid-Cap Biotech Watch List: Updated 6/12/18 After Huge ASCO Rally

  Updated 6/18 pre-market Biotech Update for Week Ending 6/15 A relatively quiet less volatile week with the bullish trend intact at “triple-top” with XBI at $97 level. However, NASDAQ weakness today could blunt run in biotechs. We probably had one of the best ASCO stock rallies on record in 2018 focusing on small and […]

Continue Reading 0

Mid-Cap Biotechs Lead the Market: Pre-ASCO Scoreboard…Updates 6/4/18

6/4/18…after close Update-2…IBB down 0.65%, XBI down 0.22%.  Momentum Waning Big Winners Today : BLUE, FMI, GHDX, IMMU, MRK It would appear that biotech stocks need to be bought prior to ASCO as has been then trend in the past i.e sell before the news. However there will be some clear cut winners after the Meeting. […]

Continue Reading 0